BioGaia’s oral health probiotic effective in patients with dental implants
Inflammation and other complications with dental implants are common. Results from a double-blind randomized controlled trial in 34 patients with implants show that 30 days of supplementation with Lactobacillus reuteri Prodentis significantly reduced inflammation related to implants. This is the first published data with Lactobacillus reuteri Prodentis in patients with dental implants.
Peri-implant mucositis is an inflammatory condition affecting the gums around dental implants. If not treated, it may lead to a worsened condition, peri-implantitis, which may need surgery or replacement of the dental implant. Nearly one out of five patients will suffer from peri-implantitis five to ten years after the dental implants have been inserted. Currently there are no consensus guidelines for the treatment of peri-implantitis.
“Our study shows that treatment with Lactobacillus reuteri Prodentis in patients with implants and mucositis both improved clinical parameters as well as reduced cytokine levels compared to placebo. Supplementation of Lactobacillus reuteri Prodentis may therefore be a good alternative for both treatment of peri-implant disease and its prevention”, says Antonio J Flichy-Fernández, DDS, PhD, Department of Oral Surgery and Implantology, University of Valencia, Spain.
“Ten years ago peri-implantitis was a condition that hardly existed. Today it is on the rise and a major concern given the increasing number of patients with dental implants. This study shows that Lactobacillus reuteri Prodentis is effective in both the treatment and prevention of dental implant diseases and will support the growth of BioGaia’s business in dental clinics around the world”, says Peter Rothschild, President, BioGaia.
New confirming results in periodontitis
Another study with Lactobacillus reuteri Prodentis was also recently published, in Journal of Clinical Periodontology. This evaluated the effects of Lactobacillus reuteri Prodentis as an adjunct to periodontal treatment. It demonstrated that supplementation resulted in a lasting effect for up to six months.
This is the fifth clinical study (Vivekananda 2010, Vicario 2012, Teughels 2013, Szkaradkiewicz 2013) confirming that Lactobacillus reuteri Prodentis is effective as an adjunct to standard periodontal treatment.
BioGaia ProDentis is a food supplement, which contains Lactobacillus reuteri Prodentis. It is available in more than 20 countries.
Latest press releases from BioGaia
2015-02-23 BioGaia subsidiary Infant Bacterial therapeutics gets Orphan Drug Designation in Europe
2015-02-12 BioGaia AB – Year-end report 2014
2015-02-10 Nestlé launches new product with BioGaia’s probiotic
BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 9 March 2015, 09:00 am CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com